The therapeutic response to MDM2 inhibition is strongly influenced by the tumor microenvironment, encompassing immune regulation, metabolic adaptation, and stromal-immune crosstalk (Wang W. et al., 2024). The gene discussed is MDM2; the disease is neoplasm.